Long intergenic non‑coding RNA 00467 promotes lung adenocarcinoma proliferation, migration and invasion by binding with EZH2 and repressing HTRA3 expression

Wang,Xianghai; Liu,Hongbing; Shen,Kaikai; Pan,Xianhui; Wei,Yuqing; Lv,Tangfeng; Song,Yong

doi:10.3892/mmr.2019.10292

Long intergenic non‑coding RNA 00467 promotes lung adenocarcinoma proliferation, migration and invasion by binding with EZH2 and repressing HTRA3 expression

Authors:
- Xianghai Wang
- Hongbing Liu
- Kaikai Shen
- Xianhui Pan
- Yuqing Wei
- Tangfeng Lv
- Yong Song
View Affiliations

Affiliations: Department of Respiratory Medicine, Jinling Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 210002, P.R. China, Department of Respiratory Medicine, Yijishan Hospital, Wannan Medical College, Wuhu, Anhui 241001, P.R. China, Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002, P.R. China
Published online on: May 23, 2019 https://doi.org/10.3892/mmr.2019.10292
Pages: 640-654
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNAs (lncRNAs) have been identified to serve an important role in the occurrence, development and metastasis of tumours. However, the role of linc00467 in lung adenocarcinoma (LAD) is unclear. In the present study, it was demonstrated that linc00467 expression was upregulated in human lung tumour tissues compared with normal tissues. In addition, high levels of linc00467 expression were associated with larger tumour sizes and later TNM stages. Functional experiments suggested that linc00467 promoted LAD cell proliferation, migration and invasion, and inhibited apoptosis in vitro. Knockdown of linc00467 altered the expression of downstream genes, including HtrA serine peptidase 3 (HTRA3), and RNA immunoprecipitation and chromatin immunoprecipitation assays indicated that linc00467 recruited EZH2 to the HTRA3 promoter to inhibit its expression. Taken together, the results of the present study indicated that linc00467 served an oncogenic role in LAD tumourigenesis, suggesting that it may be used as a novel diagnostic biomarker and therapeutic target for LAD.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A and de Marinis F: Bone and brain metastasis in lung cancer: Recent advances in therapeutic strategies. Ther Adv Med Oncol. 6:101–114. 2014. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
4	Wang PQ, Wu YX, Zhong XD, Liu B and Qiao G: Prognostic significance of overexpressed long non-coding RNA TUG1 in patients with clear cell renal cell carcinoma. Eur Rev Med Pharmacol Sci. 21:82–86. 2017.PubMed/NCBI
5	Wang Y, Zhang W, Wang Y and Wang S: HOXD-AS1 promotes cell proliferation, migration and invasion through miR-608/FZD4 axis in ovarian cancer. Am J Cancer Res. 8:170–182. 2018.PubMed/NCBI
6	Ricciuti B, Mencaroni C, Paglialunga L, Paciullo F, Crino L, Chiari R and Metro G: Long noncoding RNAs: New insights into non-small cell lung cancer biology, diagnosis and therapy. Med Oncol. 33:182016. View Article : Google Scholar : PubMed/NCBI
7	Zhang Y and Tang L: The application of lncRNAs in cancer treatment and diagnosis. Recent Pat Anticancer Drug Discov. 13:292–301. 2018. View Article : Google Scholar : PubMed/NCBI
8	Chen L, Dzakah EE and Shan G: Targetable long non-coding RNAs in cancer treatments. Cancer Lett. 418:119–124. 2018. View Article : Google Scholar : PubMed/NCBI
9	Chandra Gupta S and Nandan Tripathi Y: Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int J Cancer. 140:1955–1967. 2017. View Article : Google Scholar : PubMed/NCBI
10	Atmadibrata B, Liu PY, Sokolowski N, Zhang L, Wong M, Tee AE, Marshall GM and Liu T: The novel long noncoding RNA linc00467 promotes cell survival but is down·regulated by N-Myc. Plos One. 9:e881122014. View Article : Google Scholar : PubMed/NCBI
11	Singh H, Li Y, Fuller PJ, Harrison C, Rao J, Stephens AN and Nie G: HtrA3 is downregulated in cancer cell lines and significantly reduced in primary serous and granulosa cell ovarian tumors. J Cancer. 4:152–164. 2013. View Article : Google Scholar : PubMed/NCBI
12	Li Y, Gong L, Qi R, Sun Q, Xia X, He H, Ren J, Zhu O and Zhou D: Paeoniflorin suppresses pancreatic cancer cell growth by upregulating HTRA3 expression. Drug Des Devel Ther. 11:2481–2491. 2017. View Article : Google Scholar : PubMed/NCBI
13	Yin Y, Wu M, Nie G, Wang K, Wei J, Zhao M and Chen Q: HtrA3 is negatively correlated with lymph node metastasis in invasive ductal breast cancer. Tumour Biol. 34:3611–3617. 2013. View Article : Google Scholar : PubMed/NCBI
14	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI
15	Kim D, Langmead B and Salzberg SL: HISAT: A fast spliced aligner with low memory requirements. Nat Methods. 12:357–360. 2015. View Article : Google Scholar : PubMed/NCBI
16	Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT and Salzberg SL: StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 33:290–295. 2015. View Article : Google Scholar : PubMed/NCBI
17	Pertea M, Kim D, Pertea GM, Leek JT and Salzberg SL: Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 11:1650–1667. 2016. View Article : Google Scholar : PubMed/NCBI
18	Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G, Garg K, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International multidisciplinary classification of lung adenocarcinoma: Executive summary. Proc Am Thorac Soc. 8:381–385. 2011. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Malek E, Jagannathan S and Driscoll JJ: Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget. 5:8027–8038. 2014. View Article : Google Scholar : PubMed/NCBI
21	Chen J, Wang R, Zhang K and Chen LB: Long non-coding RNAs in non-small cell lung cancer as biomarkers and therapeutic targets. J Cell Mol Med. 18:2425–2436. 2014. View Article : Google Scholar : PubMed/NCBI
22	Xia H, Jing H, Li Y and Lv X: Long noncoding RNA HOXD-AS1 promotes non-small cell lung cancer migration and invasion through regulating miR-133b/MMP9 axis. Biomed Pharmacother. 106:156–162. 2018. View Article : Google Scholar : PubMed/NCBI
23	Quinn JJ and Chang HY: Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 17:47–62. 2016. View Article : Google Scholar : PubMed/NCBI
24	Di Gesualdo F, Capaccioli S and Lulli M: A pathophysiological view of the long non-coding RNA world. Oncotarget. 5:10976–10996. 2014. View Article : Google Scholar : PubMed/NCBI
25	Yang L, Ge D, Chen X, Qiu J, Yin Z, Zheng S and Jiang C: FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2. Biochem Biophys Res Commun. 502:493–500. 2018. View Article : Google Scholar : PubMed/NCBI
26	Sun TT, He J, Liang Q, Ren LL, Yan TT, Yu TC, Tang JY, Bao YJ, Hu Y, Lin Y, et al: A novel lncRNA GClnc1 promotes gastric carcinogenesis and may act as a modular scaffold of WDR5 and KAT2A complexes to specify the histone modification pattern. Cancer Discov. 6:784–801. 2016. View Article : Google Scholar : PubMed/NCBI
27	Takashina T, Kinoshita I, Kikuchi J, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Nishimura M and Dosaka-Akita H: Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells. Cancer Sci. 107:955–962. 2016. View Article : Google Scholar : PubMed/NCBI
28	Liu S, Chen D, Shen W, Chen L, Yu A, Fu H, Sun K and Sun X: EZH2 mediates the regulation of S100A4 on E-cadherin expression and the proliferation, migration of gastric cancer cells. Hepatogastroenterology. 62:737–741. 2015.PubMed/NCBI
29	McDevitt MA: Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies. Semin Oncol. 39:109–122. 2012. View Article : Google Scholar : PubMed/NCBI
30	van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJ and Raaphorst FM: Polycomb-group oncogenes EZH2,BMIl and RINGl are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol. 52:455–463. 2007. View Article : Google Scholar : PubMed/NCBI
31	Yoo KH and Hennighausen L: EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci. 8:59–65. 2012. View Article : Google Scholar : PubMed/NCBI
32	Benard A, Goossens-Beumer IJ, van Hoesel AQ, Horati H, Putter H, Zeestraten EC, van de Velde CJ and Kuppen PJ: Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer. PLoS One. 9:e1082652014. View Article : Google Scholar : PubMed/NCBI
33	Gannon OM, Merida de Long L, Endo-Munoz L, Hazar-Rethinam M and Saunders NA: Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation. Clin Cancer Res. 19:428–441. 2013. View Article : Google Scholar : PubMed/NCBI
34	Saito M, Saito K, Shiraishi K, Maeda D, Suzuki H, Minamiya Y, Kono K, Kohno T and Goto A: Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol Clin Oncol. 8:310–314. 2018.PubMed/NCBI
35	Clausen T, Southan C and Ehrmann M: The HtrA family of proteases: Implications for protein composition and cell fate. Mol Cell. 10:443–455. 2002. View Article : Google Scholar : PubMed/NCBI
36	Zhao J, Zhang J, Zhang X, Feng M and Qu J: High temperature requirement A3 (HTRA3) expression predicts postoperative recurrence and survival in patients with non-small-cell lung cancer. Oncotarget. 7:40725–40734. 2016.PubMed/NCBI
37	Wenta T, Zurawa-Janicka D, Rychlowski M, Jarzab M, Glaza P, Lipinska A, Bienkowska-Szewczyk K, Herman-Antosiewicz A, Skorko-Glonek J and Lipinska B: HtrA3 is a cellular partner of cytoskeleton proteins and TCP1α chaperonin. J Proteomics. 177:88–111. 2018. View Article : Google Scholar : PubMed/NCBI